SCHEMBL284945

SCHEMBL284945

ClC(Cl)(Cl)c1[c]cccc1

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19405430 0.80
SCHEMBL18242458 0.80
SCHEMBL9257902 0.80
SCHEMBL454837 0.80
SCHEMBL9201515 0.80
SCHEMBL8556914 0.80
SCHEMBL19405667 0.80
SCHEMBL5402633 0.80
SCHEMBL10631014 0.80
SCHEMBL8308460 0.77 TSHR (0.42) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1038 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114105993-B Synthesis method of chiral pyrroloimidazole compound 大连理工大学 2023-03-10 CN claimed
CN-114105993-A Synthesis method of chiral pyrroloimidazole compound 大连理工大学 2022-03-01 CN claimed
CN-109942553-B Synthesis and conversion method of chiral 3,4, 6-trisubstituted tetrahydro 2H-pyran-2-one compound 大连理工大学 2020-09-29 CN claimed
CN-109942553-A A kind of synthesis of tri- substituted-tetrahydro 2H- pyran-2-one compound of chirality 3,4,6- and its method for transformation 大连理工大学 2019-06-28 CN claimed
EP-3197507-A1 MALODOR REDUCTION COMPOSITIONS The Procter and Gamble Company (US) 2017-08-02 EP claimed
WO-2016049389-A1 MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP claimed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP claimed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US claimed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO claimed
CN-1440390-A Substituted diamine derivatives as motilin antagonists ORTHO MCNEIL PHARM INC (US) 2003-09-03 CN claimed
US-6509426-B2 Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability JAPAN POLYCHEM CORPORATION (JP) 2003-01-21 US claimed
US-20010041794-A1 Nucleotide analogs GILEAD SCIENCES, INC. 2001-11-15 US claimed
US-5798340-A ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY GILEAD SCIENCES, INC. (US) 1998-08-25 US claimed
EP-0641786-B1 Process for producing optically active alcohol SUMITOMO CHEMICAL CO (JP) 1997-08-20 EP claimed
EP-0641786-A1 Process for producing optically active alcohol SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-03-08 EP claimed
US-5144039-A Reducing prochiral ketone with metal borohydride modified with optically active amino alcohol in presence of ether or sulfide SUMITOMO ELECTRIC COMPANY, LIMITED (JP) 1992-09-01 US claimed
EP-0381434-A1 Process for producing optically active alcohol SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-08-08 EP claimed
EP-0062773-B1 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders STAUFFER CHEMICAL COMPANY (US) 1984-12-05 EP claimed
EP-0062773-A1 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders STAUFFER CHEMICAL COMPANY (US) 1982-10-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041794-A1 Nucleotide analogs PNP, NUDT1, TYMP TSHR 2855/4885LMNA 1209/4885
US-20050215526-A1 Melanin concentrating hormone receptor antagonist MCHR1, MC1R, NPY1R TSHR 17/4885LMNA 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.